Please assess the completion status of the following clinical trial:

Trial Title: Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 65 years.~* 8/8 or 7/8 HLA-identical matched sibling OR Allele level 8/8 (HLA-A, B, C, DR Beta1)matched unrelated donor or 4/6 or better HLA matched cord blood.~* Patients with high risk hematologic malignancies who are appropriate candidates for a myeloablative allogeneic stem cell transplantation.~* Patients with a history of CNS disease must have been treated and have no active CNS disease at the time of protocol treatment.~* ECOG performance status \< or equal to 2~* Patients must have adequate function of other organ systems as measured by:~* Creatinine clearance (by Cockcroft Gault equation) \> or equal to 30ml/min. Hepatic transaminases (ALT/AST) \< or equal to 4 x normal, bilirubin \< or equal to 2.0 mg/dl.~* Pulmonary function tests demonstrating FVC and FEV1 of \> or equal to 50% of predicted for age and DLCO \> or equal to 50% of predicted.~* Ejection fraction of \> or equal to 45% by echocardiogram, radionuclide scan or cardiac MRI.~* Patients must be HIV negative.~* Patients must not be pregnant.~Exclusion Criteria:~* Patients with \> 5% blasts in bone marrow or peripheral circulation.~* Uncontrolled infection.~* Class III or IV angina as per NYHA criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Transplant Recipients (Type: EXPERIMENTAL): Transplant recipients from matched sibling donors and dual cord donors. Subjects will receive plerixafor at 240 ug/kg subcutaneously every other day beginning at day +2 after transplant until day +21 or engraftment occurs.

Based on this trial design, predict the completion outcome and termination type (if applicable).